A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2023-07-15
Target enrollment:
Participant gender:
Summary
This study is about a medicine called TAK-981 given with rituximab, used to treat adults with
relapsed or refractory CD20-positive Non-Hodgkin lymphoma.
This study has 2 parts.
The main aims of the study are:
- To check for side effects from treatment with TAK-981 given with rituximab.
- To check how much TAK-981 participants can tolerate.
- To check if participants with diffuse large B-cell lymphoma or follicular lymphoma
respond well to treatment.
Participants will receive TAK-981 and rituximab in 21-day cycles. They will continue
treatment for about 12 months unless their condition gets worse (disease progression), they
cannot tolerate the treatment, or they leave the study for certain reasons.